Trials / Completed
CompletedNCT04908722
A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults
A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,609 (actual)
- Sponsor
- Janssen Vaccines & Prevention B.V. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to demonstrate non-inferiority (NI) in terms of humoral immune responses after 6 dose levels of Ad26.COV2.S.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ad26.COV2.S | Participants will receive intramuscular (IM) injections of Ad26.COV2.S. |
Timeline
- Start date
- 2021-06-18
- Primary completion
- 2023-07-10
- Completion
- 2023-07-10
- First posted
- 2021-06-01
- Last updated
- 2025-02-04
- Results posted
- 2024-05-23
Locations
43 sites across 5 countries: United States, Brazil, Germany, Poland, South Africa
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04908722. Inclusion in this directory is not an endorsement.